LONDON - RTW Biotech Opportunities Ltd, a company that invests in high-potential life sciences assets, has joined in the Series A financing of Ottimo Pharma, a biotechnology firm advancing cancer treatment with bifunctional medicines. Ottimo announced the completion of its Series A round, raising over $140 million to further develop its lead asset, Jankistomig, and other innovative cancer therapies.
Jankistomig is a first-in-class PD1/VEGFR2 bifunctional antibody aimed at treating multiple solid tumor indications. By targeting both immune checkpoint inhibition and angiogenesis, Ottimo's treatment is designed to broaden therapeutic options and enhance patient outcomes while potentially reducing healthcare costs.
The investment aligns with RTW's strategy of supporting transformative healthcare solutions. Roderick Wong, Managing Partner and CIO at RTW Investments, LP, expressed excitement about the opportunity to contribute to Ottimo's progress, stating, "The innovative approach and promising potential of Jankistomig align with our mission to invest in transformative healthcare solutions."
Ottimo Pharma is focused on developing dual-pathway therapies for solid tumors, aiming to improve on existing cancer treatments. The significant investment reflects confidence in Ottimo's approach to addressing unmet needs in oncology.
The participation of RTW Biotech Opportunities Ltd in Ottimo's funding round marks a notable endorsement of Ottimo's technology and potential impact on cancer treatment. The investment is part of RTW's broader commitment to fostering innovation in the biopharmaceutical and medical technology sectors.
This investment news is based on a press release statement from RTW Biotech Opportunities Ltd and does not include any speculative or promotional content. The forward-looking statements in the original announcement are subject to risks and uncertainties, and there is no assurance that the anticipated developments will come to fruition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.